Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Smith VK, Mansfield CA, Klaiber HA. Terrorist threats, information disclosures, and consumer sovereignty. Information economics and policy. 2013 Dec;25(4):225-34.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Chirila C, Earnshaw SR, Black L, McDade CL, Roskell NS, Shannon PR, Montorsi F, Andriole GL. Economic analysis: randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer. J Cancer Sci Ther. 2011;S3(004). doi: 10.4172/1948-5956.S3-004
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.